Will Qiagen Acquisition of IBS Impact Patent Dispute with Illumina? | GenomeWeb

Late last month, Qiagen announced that it was moving into the next-generation sequencing market, with a specific focus on clinical sequencing workflows. As part of that strategy, it acquired Intelligent Bio-Systems and said that it planned to improve IBS's existing sequencing platform, the Mini-20, to make it more suitable for commercial, clinical purposes (IS 6/26/2012).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.